GW Pharmaceuticals
GW Pharmaceuticals[edit]
GW Pharmaceuticals is a biopharmaceutical company known for its pioneering work in the development of cannabis-based medicines. Founded in 1998, the company is headquartered in Cambridge, United Kingdom. GW Pharmaceuticals is renowned for its focus on the research, development, and commercialization of cannabinoid prescription medicines using botanical extracts derived from the Cannabis sativa plant.
History[edit]
GW Pharmaceuticals was established by Dr. Geoffrey Guy and Dr. Brian Whittle with the aim of exploring the therapeutic potential of cannabinoids. The company has since become a leader in the field of cannabinoid science, conducting extensive research and clinical trials to develop innovative treatments for a variety of medical conditions.
Products[edit]
GW Pharmaceuticals is best known for its development of Epidiolex, a cannabidiol (CBD) oral solution approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with two rare and severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex was the first cannabis-derived medication to receive FDA approval.
Another notable product developed by GW Pharmaceuticals is Sativex, a mouth spray containing a combination of tetrahydrocannabinol (THC) and CBD. Sativex is approved in several countries for the treatment of spasticity due to multiple sclerosis.
Research and Development[edit]
GW Pharmaceuticals has a robust research and development program focused on exploring the potential of cannabinoids in treating a wide range of medical conditions. The company conducts clinical trials to evaluate the efficacy and safety of its products in various therapeutic areas, including neurology, oncology, and psychiatry.
Acquisition[edit]
In 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals, a global biopharmaceutical company, in a deal valued at approximately $7.2 billion. This acquisition has allowed GW Pharmaceuticals to expand its reach and continue its research into cannabinoid-based therapies under the umbrella of Jazz Pharmaceuticals.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
